US Bancorp’s Larimar Therapeutics LRMR Stock Holding History

US Bancorp’s Portfolio LRMR Stock Details LRMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.58K	Hold	1,175	–	–	﹤0.01%	3743
2026 Q1	$5.29K	Hold	1,175	–	–	﹤0.01%	3550
2025 Q4	$4.48K	Sell	1,175 -95	-7%	-$369	﹤0.01%	3577
2025 Q3	$4.1K	Buy	1,270 +95	+8%	+$356	﹤0.01%	3590
2025 Q2	$3.4K	Hold	1,175	–	–	﹤0.01%	3744
2025 Q1	$2.53K	Hold	1,175	–	–	﹤0.01%	3829
2024 Q4	$4.55K	Hold	1,175	–	–	﹤0.01%	3671
2024 Q3	$7.7K	Hold	1,175	–	–	﹤0.01%	3449
2024 Q2	$8.52K	Hold	1,175	–	–	﹤0.01%	3364
2024 Q1	$8.92K	Hold	1,175	–	–	﹤0.01%	3365
2023 Q4	$5.35K	Hold	1,175	–	–	﹤0.01%	3507
2023 Q3	$4.64K	Hold	1,175	–	–	﹤0.01%	3452
2023 Q2	$3.68K	Hold	1,175	–	–	﹤0.01%	3560
2023 Q1	$5.32K	Hold	1,175	–	–	﹤0.01%	3501
2022 Q4	$4.85K	Hold	1,175	–	–	﹤0.01%	3519
2022 Q3	$4K	Hold	1,175	–	–	﹤0.01%	3672
2022 Q2	$2K	Hold	1,175	–	–	﹤0.01%	3851
2022 Q1	$5K	Hold	1,175	–	–	﹤0.01%	3615
2021 Q4	$13K	Hold	1,175	–	–	﹤0.01%	3323
2021 Q3	$14K	Hold	1,175	–	–	﹤0.01%	3301
2021 Q2	$12K	Hold	1,175	–	–	﹤0.01%	3345
2021 Q1	$17K	Hold	1,175	–	–	﹤0.01%	3099
2020 Q4	$25K	Hold	1,175	–	–	﹤0.01%	2819
2020 Q3	$18K	Hold	1,175	–	–	﹤0.01%	2853
2020 Q2	$15K	Hold	1,175	–	–	﹤0.01%	2947
2020 Q1	$11K	Hold	1,175	–	–	﹤0.01%	2988
2019 Q4	$16K	Hold	1,175	–	–	﹤0.01%	2968
2019 Q3	$10K	Hold	1,175	–	–	﹤0.01%	3047
2019 Q2	$17K	Hold	1,175	–	–	﹤0.01%	2941
2019 Q1	$39K	Hold	1,175	–	–	﹤0.01%	2602
2018 Q4	$70K	Hold	1,175	–	–	﹤0.01%	2301
2018 Q3	$165K	Hold	1,175	–	–	﹤0.01%	1960
2018 Q2	$144K	Hold	1,175	–	–	﹤0.01%	2044
2018 Q1	$105K	Hold	1,175	–	–	﹤0.01%	2207
2017 Q4	$65K	Hold	1,175	–	–	﹤0.01%	2465
2017 Q3	$50K	Hold	1,175	–	–	﹤0.01%	2572
2017 Q2	$50K	Hold	1,175	–	–	﹤0.01%	2541
2017 Q1	$66K	Hold	1,175	–	–	﹤0.01%	2346
2016 Q4	$45K	Hold	1,175	–	–	﹤0.01%	2503
2016 Q3	$47K	Hold	1,175	–	–	﹤0.01%	2469
2016 Q2	$84K	Hold	1,175	–	–	﹤0.01%	2140
2016 Q1	$94K	Buy	+1,175	New	+$92.8K	﹤0.01%	2038

Other funds holding LRMR

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DCM

Defilade Capital Management Emeryville, California $747M AUM

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

US Bancorp's LRMR Position: Q2 2026 in Review

US Bancorp held its Larimar Therapeutics (LRMR) position steady in Q2 2026 at 1,175 shares worth $3.58K. The position accounts for ﹤0.01% of the portfolio, ranked #3743.

US Bancorp first reported a position in LRMR in Q1 2016 and has held it in 42 quarters since. The position peaked at $165K in Q3 2018. 163 funds tracked by Wall St. Rank hold LRMR as of Q2 2026.

US Bancorp held 1,175 shares of Larimar Therapeutics worth $3.58K as of Q2 2026.
US Bancorp left its Larimar Therapeutics share count unchanged in Q2 2026.
Larimar Therapeutics made up ﹤0.01% of US Bancorp's portfolio in Q2 2026, its #3743 holding.
US Bancorp first reported a position in Larimar Therapeutics in Q1 2016 and has held it in 42 quarters since.
US Bancorp's Larimar Therapeutics position peaked at $165K in Q3 2018.
163 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.